ARRS 2022 Abstracts

RETURN TO ABSTRACT LISTING


E2060. Liver Fibrosis in Asian Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
Authors
  1. Heon-Ju Kwon; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
  2. Won Sohn; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
  3. Yong Kyun Cho; Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine
Objective:
This study aimed to evaluate risk factors associated with liver fibrosis in metabolic dysfunction-associated fatty liver disease (MAFLD).

Materials and Methods:
A cross-sectional study of 967 Korean patients with MAFLD involved a cohort from a health screening program during the years 2015–2018. The patients were classified into four MAFLD subgroups: group 1 (overweight), group 2 (obese), group 3 (lean/normal weight with metabolic abnormalities), and group 4 (diabetes). Liver fibrosis was assessed based on liver stiffness measurement (LSM) value using 2D real-time magnetic resonance elastography. We investigated differences in liver fibrosis according to MAFLD subgroup classification and determined the risk factors for significant fibrosis.

Results:
The mean age was 50.8 years, and 869 (90%) patients were male. The mean value of LSM in magnetic resonance elastography was 2.48 ± 0.47 kPa. Significant fibrosis (LSM = 2.97 kPa) was observed in 66 (6.8%) of 967 patients. The proportion of significant fibrosis in MAFLD group 1, group 2, group 3, and group 4 was 1.3%, 5.5%, 6.4%, and 18.9%, respectively (p < .001). Multivariable analysis indicated that the risk factors for significant fibrosis were: serum ferritin = 300 ng/mL (odds ratio [OR], 1.96; 95% confidence interval [CI], 1.10–3.49; p = .023), fibrosis-4 = 1.3 (OR, 2.97; 95% CI, 1.68–5.24; p < .001), homeostatic model assessment of insulin resistance = 2.0 (OR, 2.60; 95% CI, 1.25–5.43; p = .011), metabolic syndrome (OR, 2.53; 95% CI, 1.31–4.88; p = .006), and MAFLD group 4 (OR, 6.93; 95% CI, 1.96–24.51; p = .003); however, the etiology of liver disease was not statistically associated with liver fibrosis.

Conclusion:
Liver fibrosis in patients with MAFLD varies according to subgroup classification based on diabetes, body mass index, and metabolic risk factors.